10-Q: Cardiff Lexington Reports Q1 2026 Financials, Faces Net Loss

Cardiff Lexington Corporation reported a net loss of $3.09 million for the first quarter of 2026, a significant increase from the prior year's loss, driven by higher interest expenses and derivative liability losses.

Summary

• Cardiff Lexington Corporation reported a net loss of $3,092,074 for the three months ended March 31, 2026, compared to a net loss of $450,777 for the same period in 2025.
• Total revenue decreased by 23.78% to $2,222,280 for Q1 2026 from $2,915,567 in Q1 2025, primarily due to a decrease in surgical procedures and a lower realization rate.
• Gross profit decreased by 28.39% to $1,318,055, with gross margin declining from 63.13% to 59.31%.
• Selling, general, and administrative expenses decreased by 9.07% to $1,164,425, but as a percentage of revenue, they increased from 43.92% to 52.40%.
• Total other expenses significantly increased to $2,580,915 from $994,711, largely due to a $1,910,737 interest expense and a $668,821 loss on derivative liabilities.
• The company had $683,507 in cash as of March 31, 2026, and believes current working capital and expected financing are sufficient for at least one year, but additional capital is required for continued operations and acquisitions.
• A lawsuit was filed by former Chairman Daniel R. Thompson alleging breach of contract and seeking unspecified damages.
• The company implemented a 1-for-3 reverse stock split effective January 12, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the increased net loss, declining revenue, higher expenses, and the explicit mention of substantial doubt about the company's ability to continue as a going concern, requiring significant future financing.

Positives

• The company has $683,507 in cash as of March 31, 2026.
• The company believes current working capital and expected additional financing should be sufficient to fund operations and satisfy obligations for at least one year.
• The company has a line of credit with an unused balance of $4,077,827 as of March 31, 2026.
• The company has $540,000 in land assets.
• The company has $5,666,608 in goodwill.

Negatives

• The company reported a net loss of $3,092,074 for the three months ended March 31, 2026, an increase from the $450,777 net loss in the prior year's comparable period.
• Revenue decreased by 23.78% to $2,222,280 for the three months ended March 31, 2026.
• Gross margin decreased from 63.13% to 59.31%.
• Selling, general, and administrative expenses increased as a percentage of revenue from 43.92% to 52.40%.
• Interest expense increased significantly to $1,910,737 from $993,114.
• The company recorded a $668,821 loss on derivative liabilities.
• The company has an accumulated deficit of $82,855,513 as of March 31, 2026.
• The company has negative cash flow from operations of $16,730 for the three months ended March 31, 2026.
• The company's ability to continue as a going concern is dependent on additional cash infusions, and there is no assurance that sufficient capital will be obtained.
• A former Chairman has filed a lawsuit alleging breach of contract and seeking unspecified damages.

Risks

• The company's ability to continue as a going concern is dependent upon additional cash infusions, and there is no assurance that sufficient capital will be obtained from debt or equity transactions or from operations in the necessary time frame or on terms acceptable to it.
• If the company is unable to raise sufficient funds, it may be required to curtail its operating plans, and increases in expenses may require cost reductions.
• There is no assurance that the company will be able to operate profitably on a consistent basis, or at all, in the future.
• If the company does not raise sufficient funds, it may cause cessation of operations.
• The company is subject to litigation from its former Chairman, Daniel R. Thompson, which could have a material adverse effect on its business, financial condition, results of operations, cash flows, and prospects.
• The company's convertible notes contain complex features, including variable conversion pricing, look-back provisions, and default adjustments, which contribute to derivative liability accounting and potential financial volatility.
• The company's healthcare revenue is dependent on settlement realization rates, which decreased in the first quarter of 2026 compared to the prior year.

Future Outlook

The company believes its current working capital and expected additional financing will be sufficient to fund operations for at least one year. However, additional capital from new financing and/or future equity raises is required for continued operations and to execute its business plan, including acquiring additional businesses. The amount of funds needed is estimated between $5 million to $10 million, depending on acquisition terms. There is no guarantee that financing will be available on acceptable terms, or at all.

Management Comments

• Management believes that current working capital and current and expected additional financing should be sufficient to fund operations and satisfy its obligations as they come due for at least one year from the financial statement issuance date.
• Additional funds from new financing and/or future equity raises are required for continued operations and to execute its business plan and its strategy of acquiring additional businesses.
• There can be no assurance that the Company will be able to obtain sufficient capital from debt or equity transactions or from operations in the necessary time frame or on terms acceptable to it.
• Should the Company be unable to raise sufficient funds, it may be required to curtail its operating plans.
• The Company intends to vigorously defend against Mr. Thompson's claims.

Industry Context

StockSavvy.ai notes that Cardiff Lexington Corporation operates in the healthcare industry, specifically focusing on acquiring and building niche healthcare clinics in orthopedics, spine care, and pain management. The company's reliance on plaintiff-related medical servicing, insulated by letters of protection, is a specific niche within the healthcare sector. The increased net loss and revenue decline in the current quarter, coupled with significant interest expenses and derivative liability losses, highlight the financial pressures many companies in growth-oriented or acquisition-heavy sectors face, especially when dealing with complex financing instruments like convertible notes.

Comparison to Industry Standards

• The company's revenue realization rate of 41% for Q1 2026 is lower than the 44% realized in Q1 2025, indicating a potential challenge in collecting receivables compared to the previous year.
• The company's gross margin of 59.31% is lower than the industry average for specialized healthcare services, which can vary widely but often aims for higher margins through efficient operations and strong payer contracts.
• The significant increase in interest expense and derivative liability losses suggests a higher cost of capital or more complex financial instruments compared to industry peers that may have simpler debt structures or stronger balance sheets.
• The company's net loss of $3.09 million in Q1 2026, compared to a smaller loss in Q1 2025, indicates a worsening financial performance relative to its own historical results, and potentially against industry benchmarks for companies of similar size and stage.

Legal Proceedings

• Daniel R. Thompson, former Chairman of the Board and significant stockholder, commenced a lawsuit against the Company on May 1, 2026, alleging breach of contract, breach of the implied covenant of good faith and fair dealing, and unjust enrichment. He claims the Company failed to provide restricted preferred stock and separation compensation, and improperly deferred accrued salary and other compensation. Damages are alleged to be in excess of $15,000 for each claim. Mr. Thompson also seeks declaratory relief regarding compensation owed and the validity of a conversion agreement, contending he revoked it or it is unenforceable, or seeking reformation.
• The Company intends to vigorously defend against Mr. Thompson's claims, but is unable to estimate potential loss due to the preliminary stage of the case.

Related Party Transactions

• On March 6, 2026, the Company issued a promissory note for $116,667 to Daniel Thompson (former Chairman) to resolve outstanding accrued compensation, bearing 10% annual interest.
• On March 6, 2026, deferred compensation of $2,352,994 owed to Daniel Thompson was cancelled in exchange for 588,249 shares of common stock.
• On January 29, 2026, deferred compensation of $2,365,242 owed to Alex Cunningham (CEO) was cancelled in exchange for 556,528 shares of common stock.
• On December 21, 2025, promissory notes totaling $1,085,703 were issued to employees for bonuses, including $460,000 to Alex Cunningham and $460,000 to Daniel Thompson, bearing 5% annual interest and maturing June 30, 2026.
• Amounts due from previous owners of Edge View (now managers) totaling $4,979 are outstanding and do not bear interest.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of common stock upon conversion of convertible notes and preferred stock dividends.
• The company's financial distress and potential cessation of operations could negatively impact all stakeholders.
• The lawsuit filed by the former Chairman could result in significant legal costs and potential financial liabilities for the company, impacting shareholder value.
• The company's need for additional capital may lead to equity financings that dilute existing shareholders.
• Creditors may face increased risk due to the company's going concern issues and reliance on debt financing.

Next Steps

• The company needs to secure additional capital to fund operations and pursue acquisitions.
• The company will continue to defend against the lawsuit filed by Daniel R. Thompson.
• The company will monitor and manage its convertible notes and associated derivative liabilities.
• The company will continue to evaluate its revenue realization rates and collection processes.

Key Dates

Recommendation

The company exhibits significant financial distress, including a widening net loss, declining revenues, and substantial debt obligations. The explicit mention of substantial doubt about its ability to continue as a going concern, coupled with the need for significant future capital raises and ongoing litigation from a former executive, presents a high-risk investment profile. The complex financial instruments, such as convertible notes with derivative features, add further uncertainty. Investors should consider the significant downside risk and lack of clear path to profitability.

Keywords

Cardiff Lexington Corporation, Form 10-Q, Quarterly Report, Financial Statements, Revenue, Net Loss, Convertible Notes, Derivative Liabilities, Interest Expense, Going Concern, Stock Split, Lawsuit